LDX Discussion, page-1121

So the highlighted text below is notable for a particular reason in relation to future sales.

While FebriDx is available for purchase and for use in the USA and in various other countries, i believe the current use of FebriDx is applied on an adhoc basis (meaning that there is no formal decision making process for clinicians to use when encountering a patient that may benefit from a FebriDx test. Currently, each clinician would either use FebriDX, or not use FebriDx, based on their own decision making process at the time).

However, it seems that Lumos is proposing an intention to formalise the use of FebriDx in a clinical environment under certain conditions. That means that clinicians would be formally told by Leadership (potentially Govt level or possibly Organisational level) to use FebriDx under certain conditions (for example, if a patient presents with a chest infection, Leadership would formally instruct each clinician to do a FebriDx test as a part of the clinicians engagement with that patient).

The above described is how i understand the highlighted statement within the below screenshot (i.e. "implementing FebriDx into clinical pathways and triage workflows").

The positive aspect of Lumos doing this is that future sales of FebriDx become almost guaranteed because each clinician is explicitly told to use FebriDX whenever a patient presents with a chest infection. However, the slight challenge with doing this is that it can take a little time to establish these "workflows" and "treatment pathways" into each clinical practice.

The above reasoning is why i have previously said that arbitrary sales figures and/or timeframes set by random people on HotCopper are not a reliable test for the future success of LDX (these random people put forward random sales figures and suggest that LDX should achieve these sales or it will be a disaster, but they do not realise that LDX has a clear plan to achieve regular and ongoing sales by establishing "workflows" and "treatment pathways" into each clinical practice).

IMO, LDX will be successful in establishing "FebriDx into clinical pathways and triage workflows" and will therefore successfully secure an ongoing and increasing future sales channel for FebriDx (although i can not be certain of the timeframe it may take to do so).

IMO, LDX has some significant upside potential.